Sinopia Biosciences scores NIH grant to supercharge AI-driven drug discovery
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Subscribe To Our Newsletter & Stay Updated